Curasight A/S
Curasight A/S
Project management regarding communication in connection with the company’s IPO on the Spotlight Stock Market in 2020.
Client: Curasight
Type: IPO
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.